SELECT PUBLICATIONS
André T et al; MOSAIC Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350(23):2343-51. Abstract
Baxter NN et al. Lymph node evaluation in colorectal cancer patients: A population-based study.
J Natl Cancer Inst 2005;97(3):219-25. Abstract
Berg DT. Capecitabine: A new adjuvant option for colorectal cancer.Clin J Oncol Nurs 2006;10(4):479-86. Abstract
Cai Q et al. Assessing 12 or more lymph nodes increases the proportion of stage III disease in colorectal cancer (CRC): Evidence from the Surveillance, Epidemiology and End Results (SEER) cancer registry. Proc ASCO 2007;Abstract 4016.
Cassidy J et al. Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC). Proc ASCO 2006;Abstract 3507.
Chau I, Cunningham D. Adjuvant therapy in colon cancer — What, when and how? Ann Oncol
2006;17(9):1347-59. Abstract
Chung KY, Kelsen D. Adjuvant therapy for Stage II colorectal cancer: Who and with what? Curr Treat Options Gastroenterol 2006;9(3):272-80. Abstract
De Gramont A et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. Proc ASCO 2007;Abstract 4007.
Gerbrecht BM, Kangas T. Implications of capecitabine (Xeloda) for cancer nursing practice. Eur J Oncol Nurs 2004;8(Suppl 1):63-71. Abstract
Gobel BH. Nursing considerations of bevacizumab use in multiple tumor types. Oncol Nurs Forum 2007;34(3):693-701. Abstract
Godino C et al. Nursing education as an intervention to decrease fatigue perception in oncology patients. Eur J Oncol Nurs 2006;10(2):150-5. Abstract
Grothey A et al. Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE). ASCO 2007;Abstract 4036.
Hobday TJ. An overview of approaches to adjuvant therapy for colorectal cancer in the United States.Clin Colorectal Cancer2005;5(Suppl 1):11-8. Abstract
Hochster HS et al. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 2007;[Epub ahead of print]. No abstract available
Kuebler JP et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 2007;25(16):2198-204. Abstract
Land SR et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007;25(16):2205-11. Abstract
Macleod A et al. A nurse-/pharmacy-led capecitabine clinic for colorectal cancer: Results of a prospective audit and retrospective survey of patient experiences. Eur J Oncol Nurs 2007;11(3):247-54. Abstract
Marsé H et al. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 2004;8(Suppl 1):16-30. Abstract
Mickle M, Mulcahy MF. Liver resection after FOLFOX with bevacizumab. Clin Adv Hematol Oncol 2007;5(1 Suppl 1):12-4. No abstract available
Mitchell SA et al. Putting evidence into practice: Evidence-based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs 2007;11(1):99-113. Abstract
Mitchell T. The social and emotional toll of chemotherapy — Patients' perspectives. Eur J Cancer Care (Engl) 2007;16(1):39-47. Abstract
Pessino A, Sobrero A. Optimal treatment of metastatic colorectal cancer.Expert Rev Anticancer Ther2006;6(5):801-12. Abstract
Rajput A et al. Meeting the 12 lymph nodes (LN) benchmark in colorectal cancer surgery: A comparison of NCCN and SEER data. Proc ASCO 2007;Abstract 4015.
Saif MW. Targeted agents for adjuvant therapy of colon cancer.Clin Colorectal Cancer 2006;6(1):46-51. Abstract
Saltz LB et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC).Presentation. Gastrointestinal Cancers Symposium 2007;Abstract 238.
Santoso JT et al. Cancer diagnosis and treatment: Communication accuracy between patients and their physicians. Cancer J 2006;12(1):73-6. Abstract
Sugrue MM et al. Serious arterial thromboembolic events (sATE) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV): Results from the BRiTE registry. ASCO 2007;Abstract 4136.
Viale PH. Expanded treatment options in the adjuvant therapy of colon cancer: Implications for oncology nurses.Oncol Nurs Forum2006;33(1):81-90. Abstract
Wilkes G. Peripheral neuropathy related to chemotherapy. Semin Oncol Nurs 2007;23(3):162-73. Abstract
Yoo PS et al. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer 2006;6(3):202-7. Abstract
